AddedRisk Factors
We are subject to data privacy and data protection laws, rules, and customer-imposed controls as a result of producing, collecting, processing, storing and transmitting confidential, personal and/or sensitive data in the course of our business. A significant number of countries where we operate have enacted privacy or data protection laws, rules and regulations, creating significant compliance challenges as we seek to maintain our global reach. In some cases, there are restrictions on the transfer of personal data outside the home country. More recently, privacy and data protection regulators are paying special attention to emerging issues linked to new digital technologies, such as the use of AI, biometrics, and surveillance technologies, which pose unique challenges to existing privacy and data protection paradigms. Any actual or perceived noncompliance could result in significant consequences, including, business interruption, sanctions and significant pecuniary fines, regulatory inquiries and investigations, adverse publicity, loss of competitive advantage and customer trust, as well as privacy litigation and civil lawsuits with damages, any of which may adversely affect our business, reputation and financial statements.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedRisk Factors
We may not be able to scale our manufacturing capacity to meet future demand, which could harm our business.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedRisk Factors
penalties, restraints on our business or reputational damage could have material adverse effects on our business and financial condition.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedRisk Factors
connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RemovedRisk Factors
•If we are unable to expand our DNA synthesis manufacturing capacity, we could lose revenue and our business could be harmed.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
Since our inception, substantially all of our resources have been dedicated to the development of our DNA synthesis platform and our sample preparation kit for NGS. We believe that we will continue to expend substantial resources for the foreseeable future as we continue to expand our production capabilities and enter additional markets we may choose to pursue, including new COVID-19 testing products, pharmaceutical biologics drug discovery and digital data storage in DNA. These expenditures are expected to include costs associated with research and development, increasing manufacturing capabilities, including operating costs of our new Wilsonville, Oregon facility, and increasing supply capabilities as well as marketing and sales capabilities of existing and new products. In addition, other unanticipated costs may arise.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
•delay, limit, reduce or terminate our manufacturing, research and development activities; or
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
•delay, limit, reduce or terminate our establishment of marketing and sales capabilities or other activities that may be necessary to generate revenue and achieve profitability.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
affected. Cyberattacks and security vulnerabilities could lead to reduced revenue, increased costs, liability claims, or harm to our reputation or competitive position.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
Our future revenue growth and market potential may depend on our ability to leverage our DNA synthesis platform together with our custom libraries and other proprietary tools, such as our antibody discovery and optimization platform, in adjacent businesses such as pharmaceutical biologics drug discovery and digital data storage in DNA. There can be no assurance that we can continue to utilize our biopharma services offerings to accelerate the lead identification and lead optimization steps of antibody discovery or to discover more effective antibody drugs. In addition, our technology may not develop in a way that allows data storage in DNA to become cost competitive with traditional data storage media or in a way that otherwise enables us to address the markets opportunities that we believe exist. If we are unable to expand into adjacent addressable markets, our business, financial position and results of operations could be negatively impacted.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
a result, revenue from these sources may vary significantly due to factors that can be difficult to forecast. Any delay or reduction in purchases by customers and potential customers or our inability to forecast fluctuations in demand could harm our future operating results.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
assurance that we will undertake or successfully complete any collaborations, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our products and technologies.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
We believe that developing and maintaining our brand is important to our success and that our financial success is influenced by the perception of our brand by our customers. Furthermore, the importance of our brand recognition may become even greater to the extent that competitors offer more products similar to ours. Many factors, some of which are beyond our control, are important to maintaining our reputation and brand. These factors include our ability to comply with ethical, social, product, labor and environmental standards. Any actual or perceived failure in compliance with such standards could damage our reputation and brand.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
additional regulatory controls including enforcement action, administrative and judicial sanctions, all of which could adversely affect our business, financial condition, or results of operations. See "Business-Government regulation-FDA".
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
Sales to our customers are generally made on open credit terms. Management maintains an allowance for potential credit losses. If our customers’ cash flow, working capital, financial conditions or results of operations deteriorate, they may be unable or even unwilling to pay trade receivables owed to us promptly or at all. As a result, we could be exposed to a certain level of credit risk. If a major customer experiences, or a significant number of customers experience, financial difficulties, the effect on us could be material and have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedRisk Factors
Patents have a limited lifespan. Patent terms may be shortened or lengthened by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates, and patent term extensions. Although extensions may be available,
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RewordedRisk Factors
We While we expect that our existing cash and cash, cash equivalents will be and short-term investments are sufficient to fund our planned operating expenses, capital expenditure requirements and debt service payments through at least the next 12 months. months, our operating plan may change as a result of factors currently unknown to us, and as a result, we have sought and may in the future need to seek additional funds sooner than planned.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
If adequate funds are not available to us on a timely basis, we may be required to: to delay, limit, reduce or terminate our manufacturing, research and development activities, marketing and sales capabilities or other activities that may be necessary to generate revenue and achieve profitability.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our technology and the production process for our DNA synthesis equipment and tools are complex, involving specialized parts, and we We may encounter unexpected difficulties in the manufacture, improvement manufacturing, improving or increasing the capacity of our DNA synthesis equipment and tools, and addressing these difficulties may cause us to divert our time and resources from our other product offerings.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
We have established an international trade compliance program that encompasses best practices for preventing, detecting and addressing noncompliance with international trade restraints; however, we could fail to observe the compliance program requirements in a manner that leaves us in noncompliance with export controls or other international trade restraints.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, our Our guidance is only an estimate of what management believes is realizable as of the date of release. release, and some or all of the assumptions underlying the guidance furnished by us may not materialize or may change significantly.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our inability to continue these initiatives and initiate new research and development efforts could result in a failure to develop or delay in developing new products, improve upon existing products such that sectors such as pharmaceutical biologics drug discovery, DNA library creation and data storage may never be fully developed, and products, or expand our addressable market, which could have a material and adverse impact on our sales, business, financial position and results of operations.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
In addition, shortages of raw materials or component parts or an increase in the cost of the raw materials or component parts we use could result in decreased revenue or could impair our ability to maintain or expand our business.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
The Federal Select Agent Program, or the FSAP, FSAP involves rules administered by the Centers for Disease Control and Prevention and Toxins CDC and the Animal and Plant Health Inspection Service APHIS that regulate possession, use and transfer of biological select agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license intellectual property that we may need to operate our business.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Evolving Increasing scrutiny and evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, from investors, lenders, customers, government regulators and other market participants may impose additional costs and expose us to reputational and other risks.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedRisk Factors
Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. practices and corporate social responsibility endeavors and reporting and may use these factors to guide investment strategies.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
Quiet changesRisk Factors
Many of these Our employees could leave our Company with little or no prior notice and would be free to work for a competitor.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
Quiet changesRisk Factors
With respect to our Wilsonville facility, if regulatory, manufacturing, or other problems require us to discontinue production at the facility, we will may not be able to manufacture our synthetic genes, oligo pools or selected NGS products or create our DNA libraries, which would adversely impact our business.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
Quiet changesRisk Factors
Additional funds funds, if needed, may not be available when we need them, on terms that are acceptable to us, or at all.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
Quiet changesRisk Factors
As we move into new markets and applications for our products and processes, incumbent participants in such markets may
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
Quiet changesRisk Factors
Patent No- No. 7,805,252 owned by DNA 2.0.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
As we have moved further up the value chain from fragments to genes to preps to proteins and beyond, the strategic connection between our SynBio and Biopharma products tightens. More customers now leverage both products and services to accelerate discovery and identify breakthrough therapeutics. This growing convergence highlights the power of our integrated platform and reinforces Twist’s unique position to serve the full spectrum of innovation in discovery.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
synthetic biology and biologic drug industries as well as leveraging our investment in our manufacturing facility in Wilsonville, Oregon.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
We sold our DNA data storage business to Atlas Data Storage, Inc. ("Atlas"), a newly formed company, that will focus solely on DNA data storage technology and commercialization, with $155.0 million in seed financing round from third-party investors. The purpose of the transaction was to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors. Under the terms of the contribution agreement executed with Atlas, we assigned and licensed our DNA data storage technology to Atlas in exchange of receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. We retained an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas’ products and services.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
Financial highlights from fiscal year 2025 compared with fiscal year 2024 include:
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
•Gross margin increased to 50.7% from 42.6%, mainly due to increase in revenues and holding fixed manufacturing costs relatively flat and driving additional cost savings through continuous process improvement initiatives;
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
•Loss from operations decreased to $(136.3) million from $(220.8) million primarily due to an increase in both revenues and gross profit for the year ended September 30, 2025, and impairment of long-lived assets recognized in the year ended September 30, 2024. Additional contributing factors were a decrease in research and development expenses offset by an increase in selling, general and administrative expenses for the year ended September 30, 2025;
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
We recognized a gain on the sale of business of $48.8 million related to the sale of our DNA digital data storage business during the year ended September 30, 2025.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
On October 21, 2024, the Company executed the Royalty Purchase Agreement with XOMA (US) LLC ("XOMA Royalty"). Under the Royalty Purchase Agreement, XOMA Royalty provided Twist Bioscience an upfront payment of $15.0 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments resulting from certain antibody discovery and biopharma services agreements between the Company and its customers (see note 17 of the consolidated financial statements included elsewhere in this Form 10-K).
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
On May 2, 2025, the Company executed the Contribution Agreement with Atlas for the sale and transfer of its DNA digital data storage assets including the related intellectual property, equipment and contracts and the license of certain other intellectual property and the license of certain other intellectual property for a consideration of 73.0 million shares of Series Seed-1 Preferred Shares of Atlas, upfront cash consideration of $2.5 million, promissory notes of $2.0 million issued by Atlas, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalty payments based on a percentage of Atlas sales of the DNA data storage products (see note 6 of the consolidated financial statements included elsewhere in this Form 10-K).
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
On November 13, 2025, we entered into a lease amendment for our facilities in South San Francisco, California. This amendment increases the leased premises by approximately 33,000 square feet in order to consolidate other offices in South San Francisco into a single location and extends the termination date of the lease until June 30, 2036. The amendment also gives us the right, on or before December 31, 2026, to elect to expand the premises to include the entire fourth floor of the building containing approximately 33,000 square feet. For more information, please see Part II, Item 9B and Note 19, Subsequent Events of the notes to our consolidated financial statements included elsewhere in this Form 10-K.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
On May 2, 2025, we measured the fair value of our investment in Series Seed-1 Preferred Stock of Atlas using the backsolve method with consideration for a lack of marketability. The backsolve method was used to solve for the implied total equity value based on the May 2025 financing by Atlas to third parties. Consideration was given to the rights and preferences of each of the classes of equity of Atlas and the expected time to a liquidity event. An option pricing allocation method, or OPM, was selected to allocate the total equity value. The OPM treats ordinary shares and preferred shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
AddedMD&A
Equity investments held by the Company lack readily determinable fair values and therefore the securities are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar equity securities of the same issuer. We review the carrying value of our equity investments for impairment whenever events or changes in business circumstances indicate the carrying amount of such asset may not be fully recoverable. Impairments, if any, are based on the excess of the carrying amount over the recoverable amount of the asset.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RemovedMD&A
We believe that the value of orders we receive is a leading indicator of our ability to generate revenue in subsequent quarters, although there can be no assurance orders will translate into revenue. We define an order as a contract with a
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
customer or purchase order from a customer, which outlines the promised goods at an agreed upon-price. In some cases, we receive a blanket purchase order from our customers, which includes pricing, payment and other terms and conditions, with quantities defined at the time each customer subsequently issues periodic releases against the blanket purchase order. We regularly assess trends relating to the value of orders we receive, including with respect to our customer concentration.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
Orders may never convert into actual revenue and the timing of delivery of our orders and recognition of revenue, if any, may vary based on the nature of the order, and there can be no assurance that orders will result in recognized revenue. The following table lists the value of orders received during the periods indicated:
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
September 30, 2024 as compared to 36.6% for the year ended September 30, 2023 mainly due to increase in revenue and the fixed costs being spread over larger revenue base resulting in an increase in gross margin.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
Cost of revenues increased from $119.3 million in the prior year to $155.4 million in the year ended September 30, 2023, an increase of $36.1 million, or 30%. The material costs increase by $14.7 million due to higher volume. Payroll, including stock-based compensation, increased $9.9 million, which included $7.4 million of savings related to the 2023 restructuring plan. Depreciation and amortization increased by $11.9 million associated with the capital investment to increase capacity. The increase in payroll costs and depreciation expenses was primarily due to the build out of the second manufacturing facility located in Wilsonville, Oregon.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
A discussion of our cost of revenues for the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 54 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
A discussion of our research and development expenses for the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 55 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
A discussion of our selling, general and administrative expenses for the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 55 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
There was no change in fair value of contingent consideration and holdbacks for the year ended September 30, 2024, as the contingent consideration and holdbacks liabilities were settled in the prior year. During the year ended September 30, 2023, we recognized a change in the fair value of contingent consideration and holdbacks of $5.5 million and $0.4 million related to the acquisitions of Abveris and iGenomX, respectively. The changes were the result of not achieving the Abveris revenue target for calendar year 2022 and a change in fair value of our stock price.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
A discussion of our change in fair value of contingent considerations and holdbacks for the year ended September 30, 2022 as compared to the year ended September 30, 2021, can be found on page 56 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
A discussion of our interest and other income (expense), net for the year ended September 30, 2022 as compared to the year ended September 30, 2021, can be found on page 56 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RemovedMD&A
Gain on deconsolidation of a subsidiary represents the gain associated with the deconsolidation of a variable interest entity, Revelar, on September 30, 2022.
Read it in 10-K Nov 18, 2024 at sec.govopen_in_new
RewordedMD&A
We recognized an impairment of intangible assets and property and equipment of $44.9 million related to the Biopharma asset group during the year ended September 30, 2024 (see discussion in critical accounting policies and estimates — impairment of long-lived assets below), as compared to impairment of property and equipment of $6.8 million during the year ended September 30, 2023, related to write-off of lab equipment and leasehold improvements for decommissioned labs and computer software. 2024.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in revenue primarily reflects growth in NGS tools revenue of $45.4 million and $39.0 million, growth in synthetic genes revenue of $19.1 million, including the Express Genes offering, which is primarily attributable to increase $20.9 million and growth in revenues from our customers in the healthcare, industrial chemicals/materials and academic research industries and an increase in the number antibody discovery revenue of customers. $3.1 million.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
In fiscal year 2024, 2025, our net cash used in the investing activities was $3.1 $24.8 million primarily as a result of purchases of property and equipment of $28.0 million, offset by the proceeds from the sale of our data storage business of $2.5 million, and the net result of purchases and maturity of investments of $2.0 million and purchases of laboratory property, equipment and computers of $5.1 $0.7 million.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
We believe that our existing cash, cash equivalents equivalents, restricted cash and short-term investments are and anticipated cash flows from operations, will be sufficient to fund meet our operating expenses, capital expenditure anticipated cash requirements and debt service payments for more than 12 months from the next 12 months. date of this Form 10-K.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
The change in operating assets and liabilities was mainly due to decreases increases in accounts receivable of $8.4 $22.4 million, inventory of $8.0 $4.2 million, prepaid and other current assets of $0.4 $3.7 million, and other non-current assets of $0.4 million, accounts payable of $11.8 million and other liabilities $2.3 $1.6 million, offset by increases in accounts payable, accrued expenses of $4.4 million expenses, and accrued compensation of $7.9 $12.7 million and other liabilities $6.6 million.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
The last day of our fiscal year is September 30, and we refer to our fiscal year ended September 30, 2022 as fiscal year 2022 or 2022, September 30, 2023 as fiscal year 2023 or 2023 and our fiscal year ended 2023, September 30, 2024 as fiscal year 2024 or 2024. 2024 and our fiscal year ended September 30, 2025 as fiscal year 2025 or 2025.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
Total selling, Selling, general and administrative expenses increased 15% 13% to $247.0 million for the year ended September 30, 2025, as compared to $218.4 million for the year ended September 30, 2024, as compared to $189.7 million for the year ended September 30, 2023. 2024.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
Research and development expenses decreased 15% 12% to $80.3 million for the year ended September 30, 2025, as compared to $90.9 million for the year ended September 30, 2024, as compared to the $106.9 million for the year ended September 30, 2023. 2024.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
Other income (expense) was $0.9 million in fiscal year 2025, as compared to $2.7 million in fiscal year 2024, as compared to $0.7 million in fiscal year 2023, mainly due to fiscal year 2024 impairment losses on an equity investment. investment recognized in fiscal year 2024.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
The increase is primarily attributable to an increase in material costs of $19.0 $9.4 million, due to higher sales volume, volume and an increase in depreciation and amortization stock-based compensation expense of $3.2 million primarily due to the capital investment to increase manufacturing capacity in prior years. $3.0 million.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
Interest income increased 7%, decreased 26%, to $15.3 $11.4 million in the year ended September 30, 2024, 2025, as compared to $14.4 $15.3 million for the year ended September 30, 2023, resulting from our cash and 2024, due to lower cash equivalents and short-term investments balance. balances and lower interest rates.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new
RewordedMD&A
We also enter into Our Biopharma revenue consists of research and development agreements that do not may include up-front payments, milestone payments, or milestone-based payments and recognize revenue on these types of agreements based on the timing of the development activities.
Read it in 10-K Nov 17, 2025 at sec.govopen_in_new